F
FibroBiologics, Inc. (FBLG)
NCM – Real Time Price. Currency in USD
1.10
+0.11 (11.11%)
At close: May 12, 2026, 4:00 PM EDT
1.06
-0.04 (-3.64%)
After-hours: May 12, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.10
+0.11 (11.11%)
At close: May 12, 2026, 4:00 PM EDT
1.06
-0.04 (-3.64%)
After-hours: May 12, 2026, 7:59 PM EDT
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
| Name | Position |
|---|---|
| Dr. Hamid Khoja Ph.D. | Chief Scientific Officer |
| Mr. Jason D. Davis CPA | Chief Financial Officer |
| Mr. Peter O'Heeron | Founder, Chairperson & CEO |
| Mr. Ruben A. Garcia J.D. | General Counsel |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 8-K | fblg-20260505.htm |
| 2026-05-05 | DEFA14A | fblg-20260504.htm |
| 2026-05-05 | ARS | ars_may_2026.pdf |
| 2026-05-01 | 8-K | fblg-20260501.htm |
| 2026-04-30 | 10-Q | fblg-20260331.htm |
| 2026-04-22 | PRE 14A | fblg-20260422.htm |
| 2026-04-20 | 8-K | fblg-20260309.htm |
| 2026-04-17 | 8-K | fblg-20260416.htm |
| 2026-04-09 | 8-K/A | fblg-20260403.htm |
| 2026-04-03 | 8-K | fblg-20260330.htm |